Breaking News Instant updates and real-time market news.

BAC

Bank of America

$30.66

0.11 (0.36%)

, GE

General Electric

$19.02

0.091 (0.48%)

08:55
01/12/18
01/12
08:55
01/12/18
08:55

Notable open interest changes for January 12th

Thursday's total option volume of 21.3 million contracts resulted in net open interest growth of 3.93 million calls and 3.63 million puts. Bank of America (BAC), General Electric (GE), Wells Fargo (WFC) and Intel (INTC) saw the greatest growth. Top five new positions opened include 78k Bank of America (BAC) Mar-18 30 calls, 32k Kinder Morgan (KMI) Jan-18 19.5 calls, 24k Alibaba (BABA) Feb-18 190 calls, 23k Alibaba (BABA) Feb-18 190 puts and 21k AT&T (T) Jan-18 36 puts.

BAC

Bank of America

$30.66

0.11 (0.36%)

GE

General Electric

$19.02

0.091 (0.48%)

WFC

Wells Fargo

$63.01

-0.11 (-0.17%)

INTC

Intel

$43.41

0.91 (2.14%)

  • 12

    Jan

  • 17

    Jan

  • 24

    Jan

  • 15

    Feb

BAC Bank of America
$30.66

0.11 (0.36%)

01/09/18
SOCG
01/09/18
DOWNGRADE
Target $33
SOCG
Hold
Bank of America downgraded to Hold from Buy at Societe Generale
Societe Generale analyst Andrew Lim downgraded Bank of America to Hold saying the stock is now fairly priced following the recent rally. The analyst raised his price target for the shares to $33 from $32.
12/20/17
WELS
12/20/17
NO CHANGE
Target $35
WELS
Outperform
Bank of America price target raised to $35 from $30 at Wells Fargo
Wells Fargo analyst Mike Mayo raised his price target for Bank of America to $35 from $30 to reflect more potential upside from a portion of higher interest rates, lower taxes, and lower cost of capital due to greater resiliency. The analyst reiterates an Outperform rating on the shares.
10/16/17
BMOC
10/16/17
NO CHANGE
Target $29
BMOC
Market Perform
Bank of America price target raised to $29 from $27 at BMO Capital
BMO Capital analyst James Fotheringham raised his price target on Bank of America following Q3 earnings to reflect higher than expected net interest margins. Fotheringham notes that among the top four banks, Bank of America is the only one offering positive return potential. The analyst also sees positive broader trends and an opportunity to buy credit-sensitive stocks, as "investors remain bullish on rates but bearish on credit". Fotheringham maintains a Market Perform rating on Bank of America.
08/09/17
WELS
08/09/17
INITIATION
WELS
Outperform
Bank of America resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Bank of America with an Outperform rating and $30 price target.
GE General Electric
$19.02

0.091 (0.48%)

12/21/17
DBAB
12/21/17
NO CHANGE
Target $15
DBAB
Sell
GE could exit Baker Hughes in 2018, says Deutsche Bank
Deutsche Bank analyst John Inch believes General Electric (GE) could exit its 62.5% ownership of Baker Hughes (BHGE) sometime in 2018. The eventual monetization and separation of GE's entire oil and gas portfolio would be consistent with management's signaling regarding its investment in Baker Hughes, Inch tells investors in a research note. GE's exit timing may not be optimal, however, considering that the pickup in industry activity is likely to continue given improved energy prices, the analyst contends. He adds that GE would forego $188M of dividend from Baker Hughes and any future additional share repurchase benefit by the company. Inch has a Sell rating on GE with a $15 price target.
01/08/18
JPMS
01/08/18
NO CHANGE
Target $16
JPMS
Underweight
JPMorgan sees 'too many risks,' cuts GE price target to $16
JPMorgan analyst C. Stephen Tusa says he sees "too many risks" to change his view on shares of General Electric. The analyst keeps an Underweight rating on the name and cut his price target for the stock to $16 from $17. There is no other company in the sector where earnings and free cash expectations were cut by 50% last year, Tusa tells investors in a research note. GE's leverage remains high and one-third of its core business lacks a "credible turnaround plan in the face of a dramatic fundamental shift," Tusa writes.
12/13/17
DBAB
12/13/17
NO CHANGE
DBAB
Sell
Deutsche concerned Ed Garden won't stay long on GE board
If Trian were to significantly reduce its ownership stake in General Electric in the coming year, from just the 80 basis points of shares it owns now, Ed Garden would likely be forced to step down from the company's board, Deutsche Bank analyst John Inch tells investors in a research note titled "GE Board risk." The analyst believes Trian could realize incremental pressure to reduce or exit its GE position, especially if the stock, as Inch expects, struggles to gain upward traction. Garden leaving the board would create "substantial headline risk," particularly given the public vote of confidence that new GE CEO John Flannery has placed in him, the analyst contends. As such, Inch sees risk that Garden may not end up serving on GE's Board over the long term. The analyst believes his selection to the board raises some questions given Trian's relatively small stake in GE. Were there not other equally qualified candidates with more prospective longevity for the position versus a hedge fund executive whose firm owns just 80 basis points of the stock, Inch asks. The analyst keeps a Sell rating on GE with a $15 price target. The shares closed yesterday up 26c to $17.97.
01/12/18
JPMS
01/12/18
NO CHANGE
JPMS
Underweight
GE management changes 'red flags for ongoing concern,' says JPMorgan
The recently announced departures of key executives at General Electric, namely Joe Mastrangelo, CEO of Gas Power Systems this week, and Rich Laxer CEO of GE Capital in late December, should not be overlooked, JPMorgan analyst C. Stephen Tusa tells investors in a research note. The departures are "further red flags around the uncertainties that remain" and for the company's "ongoing concern," Tusa contends. The analyst continues to think that calls for a bottom based "merely on stock price continue to ignore the fundamental realities at play" relating to GE's leverage, "weak" free cash flow, and "challenged" businesses like Power. Tusa thinks "there are still shoes to drop." He keeps an Underweight rating on General Electric.
WFC Wells Fargo
$63.01

-0.11 (-0.17%)

01/10/18
ATLE
01/10/18
UPGRADE
Target $61
ATLE
Overweight
Morgan Stanley upgraded on tax reform benefits at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Morgan Stanley (MS) to Overweight from Neutral, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Morgan Stanley shares to $61 from $48. The analyst also upgraded Wells Fargo (WFC) to Neutral from Underweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
ATLE
01/10/18
UPGRADE
Target $64
ATLE
Neutral
Wells Fargo upgraded to Neutral at Atlantic Equities
As previously reported, Atlantic Equities analyst John Heagerty upgraded Wells Fargo (WFC) to Neutral from Underweight, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform.
01/10/18
ATLE
01/10/18
UPGRADE
ATLE
Neutral
Wells Fargo upgraded to Neutral from Underweight at Atlantic Equities
01/10/18
01/10/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Wells Fargo (WFC) upgraded to Neutral from Underweight at Atlantic Equities by analyst John Heagerty, as his analysis leads him to increase his FY18 EPS view by 11% on average for the banks he covers. He also sees positive secondary effects for the banks from higher U.S. GDP growth. Heagerty raised his price target on Wells Fargo shares to $64 from $55. The analyst also upgraded Morgan Stanley (MS) to Overweight this morning, citing the same analysis of the potential benefits from tax reform. 2. Deere upgraded to Outperform from Sector Perform at RBC Capital by analyst Seth Weber, who said he is positive on the company's leadership position in North American farm machinery which is stabilizing and exposure to the earth moving equipment category. The analyst is also constructive on Deere's recent Wirten Group acquisition. 3. Target (TGT) upgraded to Positive from Neutral at Susquehanna. 4. State Street (STT) and BNY Mellon (BK) upgraded to Buy from Neutral at Citi, with analyst Keith Horowitz saying he thinks the trust banks are the best way to play the digital transformation to the cloud and finds the current valuation as attractive. 5. RBS (RBS) upgraded to Overweight from Equal Weight at Morgan Stanley. Analyst Alvaro Serrano also downgraded Barclays (BCS) and Lloyds Banking (LYG). This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
INTC Intel
$43.41

0.91 (2.14%)

01/05/18
RHCO
01/05/18
NO CHANGE
Target $43
RHCO
Hold
Intel security vulnerability 'brings the stock to earth', says SunTrust
SunTrust analyst William Stein keeps his Hold rating and $43 price target on Intel (INTC) in the wake of its security flaw disclosure. Stein says the rally in the stock since Q3 report was overdone to the upside, adding that the latest downside reaction, though likely overdone, puts the price around appropriate valuation. The analyst contends that consumers may favor alternative providers for parallel workload acceleration over Intel's solutions, adding that its latest issues strengthen his view on NVIDIA (NVDA).
01/05/18
ARGS
01/05/18
NO CHANGE
Target $50
ARGS
Buy
Intel chip performance issues are minor, says Argus
Argus analyst Jim Kelleher keeps his Buy rating and $50 price target on Intel amid stock price pressure from concerns about hardware vulnerabilities in the company's computer processors. Kelleher says that while Intel's reputation may have taken a hit, he sees no reason to deem the issue material for business, noting that a 2%-3% degradation in performance from installation of a software patch should be invisible to most users. The analyst says Intel stock is attractive at current levels even above the high end of its multiyear range.
01/11/18
NEED
01/11/18
NO CHANGE
Target $76
NEED
Buy
Report caused confusion about Micron, Intel 3D NAND pact, says Needham
Following a media report about Micron (MU) and Intel (INTC) parting ways in the co-development of 3D NAND, Needham analyst Rajvindra Gill spoke with Micron CFO Ernie Maddok at CES. Gill believes the report caused some confusion and he said the only change to their NAND agreement is that the two companies will go their separate ways in the development of fourth generation 3D NAND IP. Micron management's view is this is a "no-brainer," as being able to develop unique IP should allow the company to broaden its addressable market by 2021, said Gill, who added that the current pact is very strict on the usage of the co-developed IP and he sees no risk of Intel licensing to Chinese manufacturers. The analyst, who also believes current NAND pricing decline concerns are overblown, keeps a Buy rating and $76 price target on Micron shares.
01/12/18
MACQ
01/12/18
NO CHANGE
Target $51
MACQ
Outperform
Intel pullback an 'excellent opportunity,' says Macquarie
Macquarie analyst Srini Pajjuri continues to believe the impact from Meltdown/Spectre security issue to near-term financials is small. In fact, the analyst believes a slightly faster replacement of older PCs/servers is more likely than any share losses and/or delayed customer purchases. Pajjuri said ODMs and server component vendors are not seeing any delays/changes to customer buying patterns due to the Security issue. Further, there are also no indications of any price cuts, although he wouldn't be surprised to see Intel offer some concessions as a goodwill gesture down the road. The analyst said the pullback in Intel shares is an "excellent opportunity' to accumulate shares and reiterates an Outperform rating and $51 price target.

TODAY'S FREE FLY STORIES

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

CME

CME Group

$154.28

2.07 (1.36%)

, GS

Goldman Sachs

$256.12

5.15 (2.05%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Bar Association to hold annual meeting »

Derivatives & Futures…

CME

CME Group

$154.28

2.07 (1.36%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BP

BP

$42.40

-0.5 (-1.17%)

C

Citi

$78.30

0.91 (1.18%)

BAC

Bank of America

$31.72

0.24 (0.76%)

CS

Credit Suisse

$19.06

0.13 (0.69%)

CRL

Charles River

$107.89

1.22 (1.14%)

MS

Morgan Stanley

$57.46

1.62 (2.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jan

  • 24

    Jan

  • 31

    Jan

  • 01

    Feb

  • 15

    Feb

AMGN

Amgen

$189.28

1.69 (0.90%)

, BAYRY

Bayer

$32.05

0.235 (0.74%)

04:55
01/20/18
01/20
04:55
01/20/18
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

2018 ASCO…

AMGN

Amgen

$189.28

1.69 (0.90%)

BAYRY

Bayer

$32.05

0.235 (0.74%)

BLRX

BioLineRx

$1.09

-0.02 (-1.80%)

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

CELG

Celgene

$102.65

0.93 (0.91%)

DNA

Bought by RHHBY

ESALY

Eisai

$56.88

0.115 (0.20%)

EXEL

Exelixis

$28.00

0.14 (0.50%)

HALO

Halozyme

$17.98

0.13 (0.73%)

INCY

Incyte

$93.16

1.24 (1.35%)

IPSEY

Ipsen

$34.65

0.75 (2.21%)

LXRX

Lexicon

$10.44

0.2 (1.95%)

MGNX

MacroGenics

$19.19

0.3 (1.59%)

MRK

Merck

$61.28

0.15 (0.25%)

NVS

Novartis

$86.94

0.53 (0.61%)

SNY

Sanofi

$44.60

0.09 (0.20%)

ONCY

Oncolytics

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 25

    Jan

  • 25

    Jan

  • 02

    Feb

  • 03

    Feb

  • 05

    Feb

  • 08

    Feb

  • 15

    Feb

  • 16

    Feb

  • 02

    Mar

  • 05

    Mar

  • 08

    Mar

  • 25

    Mar

  • 03

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 23

    Oct

WLFC

Willis Lease

$26.66

0.05 (0.19%)

18:59
01/19/18
01/19
18:59
01/19/18
18:59
Hot Stocks
Willis Lease announces $1,000 bonus for employees »

Willis Lease announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DPS

Dr Pepper Snapple

$96.35

1.03 (1.08%)

18:13
01/19/18
01/19
18:13
01/19/18
18:13
Hot Stocks
Dr Pepper to become official sponsor of esports team TSM »

Dr Pepper announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RCII

Rent-A-Center

$11.70

0.09 (0.78%)

17:53
01/19/18
01/19
17:53
01/19/18
17:53
Hot Stocks
Vintage Capital in standstill pact with Rent-A-Center »

On January 17, Vintage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AR

Antero Resources

$18.74

-0.59 (-3.05%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Recommendations
Antero Resources analyst commentary at MUFG »

Antero Resources price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

T

AT&T

$37.21

0.06 (0.16%)

, TWX

Time Warner

$93.36

0.39 (0.42%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Periodicals
AT&T requesting docs from companies in Time Warner deal hearing, Reuters says »

AT&T (T) is…

T

AT&T

$37.21

0.06 (0.16%)

TWX

Time Warner

$93.36

0.39 (0.42%)

VZ

Verizon

$51.91

0.36 (0.70%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

DISH

Dish

$45.26

0.1 (0.22%)

CHTR

Charter

$366.05

0.8 (0.22%)

DIS

Disney

$110.59

0.17 (0.15%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 31

    Jan

  • 02

    Feb

  • 06

    Feb

  • 08

    Feb

  • 08

    Feb

GRPN

Groupon

$5.57

0.46 (9.00%)

17:44
01/19/18
01/19
17:44
01/19/18
17:44
Hot Stocks
Groupon announces Chief Product Officer Jay Sullivan resigns »

On January 17, Jay…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CELG

Celgene

$102.65

0.93 (0.91%)

17:41
01/19/18
01/19
17:41
01/19/18
17:41
Hot Stocks
Celgene's Abraxane exceeds primary endpoint target in pancreatic cancer trial »

Celgene announced primary…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 16

    Feb

  • 25

    Mar

VALU

Value Line

$19.60

0.3 (1.55%)

17:40
01/19/18
01/19
17:40
01/19/18
17:40
Hot Stocks
Value Line reaffirms $3M stock repurchase program »

The Board of Directors…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VALU

Value Line

$19.60

0.3 (1.55%)

17:39
01/19/18
01/19
17:39
01/19/18
17:39
Hot Stocks
Value Line declares special dividend of 20c per share »

Payable on March 9 to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZEAL

Zealand Pharma

$15.05

-0.78 (-4.93%)

17:34
01/19/18
01/19
17:34
01/19/18
17:34
Hot Stocks
Zealand Pharma: FDA approves IND for Phase 3 trials of dasiglucagon in CHI »

The U.S. FDA has approved…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GNMSF

Genmab

$190.75

2.75 (1.46%)

, JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

17:29
01/19/18
01/19
17:29
01/19/18
17:29
Hot Stocks
Genmab says FDA grants priority review for daratumumab »

Genmab (GNMSF) announced…

GNMSF

Genmab

$190.75

2.75 (1.46%)

JNJ

Johnson & Johnson

$147.36

0.44 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

  • 23

    Jan

  • 16

    Feb

  • 08

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.